Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;15(8):dmm049059. doi: 10.1242/dmm.049059

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 5. — Navitoclax treatment does not slow disease progression in G93A mice. (A) A chronic treatment in vivo was established with five consecutive doses followed by 2 weeks of resting. (B-D) Effect of chronic Navitoclax treatment on weight loss (B), survival time (C) and expression of SASP genes (D). (E,F) Effect of alternative senolytic regime [dasatinib and quercetin (D+Q)] in comparison to Navitoclax (Nav) on the expression levels of p16 (E) and p21 (F) mRNA in vitro. DIV, days in vitro. In A-D, n=5 from each genotype. In E and F, data shown represent three different experiments. Data are expressed as mean±s.e.m. ns, P>0.05; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 (Bonferroni post hoc analyses after two-way ANOVA).